Like many aspects of healthcare business space, drug development is in a state of constant change for the purpose of better health outcomes. Here is a sample of our summarised report of new drug therapies currently in clinical trials worldwide as reported last month 2 to 6 March 2020. During that week thirteen companies reported headline results in advancing their candidate product through clinical trials. To purchase the full report visit our i3 Shop.
| Sponsor | Study Phase | Drug Name/Code | Clinical Indication | Status | Comment | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MiNa Therapeutics | Phase I/Ib | MTL-CEBPA in combination with KEYTRUDA® (Pembrolizumab) | Advanced Solid Tumours | This Phase I/Ib TIMEPOINT study will undertake a dose-escalation followed by a dose expansion investigation. MTL‑CEBPA will be administered as an intravenous infusion once weekly in cycles of three weeks of treatment followed by one week of no treatment. Investigators at the European Society for Medical Oncology (ESMO) 2019 Congress reported that MTL-CEBPA in 39 patients with advanced liver cancer, was found to be well tolerated, showing pharmacodynamic target engagement and a reduction of suppressive immune cells in the tumour microenvironment. | TIMEPOINT is a global Phase I/Ib clinical trial being conducted in patients with solid tumour malignancies. This clinical study will evaluate the safety and tolerability of MTL-CEBPA in combination with KEYTRUDA® (Pembrolizumab) in patients who are ineligible or resistant to standard therapies. In pre-clinical investigations, MTL-CEBPA demonstrated enhanced anti-tumour activity of anti-PD1 checkpoint inhibition by decreasing immune suppression from dysregulated myeloid cells in the tumour microenvironment. |
Legal Disclaimer: All content given in this report is for informational purposes only and does not constitute clinical or financial advice. The publisher does not make any guarantee as to any results that may be obtained from using our content. To the maximum extent permitted by law, the publisher disclaims any and all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations prove to be inaccurate, incomplete or unreliable, or result in any health-related mis-treatment, adverse event or financial investment or other losses. Your use of the information contained in this report is at your own risk.
Click here to see our Previous Clinical Trial Reports.
Copyright ©i3 Consult 2020 All rights reserved.
Click this link to view our Privacy Policy